Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience.

[1]  Anoop Chullikana,et al.  Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint , 2016, Arthritis Research & Therapy.

[2]  M. Ferrante,et al.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial , 2016, The Lancet.

[3]  E. Hoffman,et al.  Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease , 2016, Clinical and Translational Gastroenterology.

[4]  B. Sands,et al.  Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  S. Kugathasan,et al.  The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn's disease – a phase 1 trial with three doses , 2016, Alimentary pharmacology & therapeutics.

[6]  D. Kondziolka,et al.  Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study , 2016, Stroke.

[7]  M. Matthay,et al.  Mitochondrial Transfer via Tunneling Nanotubes is an Important Mechanism by Which Mesenchymal Stem Cells Enhance Macrophage Phagocytosis in the In Vitro and In Vivo Models of ARDS , 2016, Stem cells.

[8]  E. Melamed,et al.  Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. , 2016, JAMA neurology.

[9]  N. Narula,et al.  Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease , 2016, Alimentary pharmacology & therapeutics.

[10]  R. Jenq,et al.  Interleukin-22 Promotes Intestinal Stem Cell-Mediated Epithelial Regeneration , 2015, Nature.

[11]  D. Artis,et al.  Innate lymphoid cells in the initiation, regulation and resolution of inflammation , 2015, Nature Medicine.

[12]  J. Turner,et al.  Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease , 2015, Mucosal Immunology.

[13]  M. Sabatino,et al.  Bone Marrow‐Derived Mesenchymal Stromal Cells Harness Purinergenic Signaling to Tolerize Human Th1 Cells In Vivo , 2015, Stem cells.

[14]  V. S. Prakash,et al.  Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. , 2015, Cytotherapy.

[15]  M. Aljurf,et al.  Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation , 2014, Journal of transplantation.

[16]  Farhaan Vahidy,et al.  Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System. , 2014, Cytotherapy.

[17]  M. Sabatino,et al.  Bone Marrow Mesenchymal Stromal Cells to Treat Tissue Damage in Allogeneic Stem Cell Transplant Recipients: Correlation of Biological Markers with Clinical Responses , 2014, Stem cells.

[18]  BattiwallaMinoo,et al.  Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. , 2014 .

[19]  J. Galipeau,et al.  IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells , 2014, The Journal of Immunology.

[20]  F. Locatelli,et al.  Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid‐refractory, grade III–IV acute graft‐versus‐host disease , 2013, British journal of haematology.

[21]  W. Fibbe,et al.  Mesenchymal stromal cells: sensors and switchers of inflammation. , 2013, Cell stem cell.

[22]  M. Benderitter,et al.  Mesenchymal Stem Cell Therapy Stimulates Endogenous Host Progenitor Cells to Improve Colonic Epithelial Regeneration , 2013, PloS one.

[23]  Wei Li,et al.  Manufacturing mesenchymal stromal cells for phase I clinical trials. , 2013, Cytotherapy.

[24]  D. García-Olmo,et al.  Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial , 2013, International Journal of Colorectal Disease.

[25]  J. Marshall,et al.  Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials , 2012, PloS one.

[26]  L. Gaboury,et al.  Adoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner. , 2012, Cytotherapy.

[27]  M. Matthay,et al.  Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[28]  J. Bolaños-Meade,et al.  Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. , 2012, Blood.

[29]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[30]  Thomas M Braun,et al.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. , 2011, Blood.

[31]  R. Romieu-Mourez,et al.  Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing , 2011, Cytotherapy.

[32]  S. Shi,et al.  Mesenchymal Stem Cell-Based Tissue Regeneration is Governed by Recipient T Lymphocyte via IFN-γ and TNF-α , 2011, Nature Medicine.

[33]  P. Mannon.  Remestemcel-L: human mesenchymal stem cells as an emerging therapy for Crohn's disease , 2011, Expert opinion on biological therapy.

[34]  M. Zago,et al.  Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. , 2011, Stem cell research.

[35]  M. Sorror,et al.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Lingyun Sun,et al.  Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease , 2011, Gut.

[37]  D. Hommes,et al.  Pretreatment with Interferon‐γ Enhances the Therapeutic Activity of Mesenchymal Stromal Cells in Animal Models of Colitis , 2011, Stem cells.

[38]  J. Kurtzberg,et al.  Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[39]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[40]  Franco Locatelli,et al.  Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease , 2011, Gut.

[41]  M. Matthay,et al.  Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37 , 2010, Stem cells.

[42]  D. Hommes,et al.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study , 2010, Gut.

[43]  P. Hanley,et al.  Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. , 2010, Cytotherapy.

[44]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[45]  I. Ko,et al.  Targeting improves MSC treatment of inflammatory bowel disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  P. Laloi,et al.  Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis , 2010, Cell Death and Differentiation.

[47]  Lingyun Sun,et al.  Allogenic bone-marrow-derived mesenchymal stem cells transplantation as a novel therapy for systemic lupus erythematosus , 2010, Expert opinion on biological therapy.

[48]  A. Keane-Myers,et al.  Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthma , 2010, Proceedings of the National Academy of Sciences.

[49]  S. Reich-Zeliger,et al.  Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells , 2009, Stem cells.

[50]  Malorye Allison.  Genzyme backs Osiris, despite Prochymal flop , 2009, Nature Biotechnology.

[51]  M. Andreeff,et al.  Direct Evidence of Mesenchymal Stem Cell Tropism for Tumor and Wounding Microenvironments Using In Vivo Bioluminescent Imaging , 2009, Stem cells.

[52]  R. Romieu-Mourez,et al.  Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. , 2009, Blood.

[53]  Peiman Hematti,et al.  Mesenchymal stem cells in hematopoietic stem cell transplantation. , 2009, Cytotherapy.

[54]  J. Perkins,et al.  Infliximab for managing steroid-refractory acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  P. Delafontaine,et al.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. , 2009, Cell stem cell.

[56]  L. Isola,et al.  Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[57]  R. Romieu-Mourez,et al.  Cytokine Modulation of TLR Expression and Activation in Mesenchymal Stromal Cells Leads to a Proinflammatory Phenotype1 , 2009, The Journal of Immunology.

[58]  C. Toma,et al.  Fate Of Culture-Expanded Mesenchymal Stem Cells in The Microvasculature: In Vivo Observations of Cell Kinetics , 2009, Circulation research.

[59]  A. M. Engemann,et al.  Clinical Utility of Rituximab in Chronic Graft-Versus-Host Disease , 2009, The Annals of pharmacotherapy.

[60]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[61]  J. Ryan,et al.  Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non‐redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cells , 2008, Clinical and experimental immunology.

[62]  Thomas M Braun,et al.  Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin , 2008, Science Translational Medicine.

[63]  Michael Loran Dustin,et al.  T Cell-Dendritic Cell Immunological Synapses Contain TCR-dependent CD28-CD80 Clusters That Recruit Protein Kinase Cθ1 , 2008, The Journal of Immunology.

[64]  G. Dini,et al.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study , 2008, The Lancet.

[65]  Allen R. Chen,et al.  Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[67]  S. Beyth,et al.  Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. , 2007, Experimental hematology.

[68]  R. Robbins,et al.  Stem cell transplantation: the lung barrier. , 2007, Transplantation proceedings.

[69]  F. Locatelli,et al.  Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.

[70]  Michael Loran Dustin,et al.  T cell-dendritic cell immunological synapses. , 2006, Current opinion in immunology.

[71]  Hanns-Ulrich Marschall,et al.  Mesenchymal Stem Cells for Treatment of Therapy-Resistant Graft-versus-Host Disease , 2006, Transplantation.

[72]  J. Galipeau,et al.  Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. , 2006, Blood.

[73]  Katrine Frønsdal,et al.  In Vitro Expansion of Human Mesenchymal Stem Cells: Choice of Serum Is a Determinant of Cell Proliferation, Differentiation, Gene Expression, and Transcriptome Stability , 2005, Stem cells.

[74]  M. Richard,et al.  Mesenchymal stem cells induce apoptosis of activated T cells , 2005, Leukemia.

[75]  T. Buchler,et al.  Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease , 2005, Annals of Hematology.

[76]  Andrea Bacigalupo,et al.  Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[77]  Ulrich Göbel,et al.  bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 20, 2013. For personal use , 2004 .

[78]  G. Vogelsang,et al.  Chronic graft versus host disease , 2004, British journal of haematology.

[79]  Shu-Ching Hsu,et al.  Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[80]  Moustapha Hassan,et al.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells , 2004, The Lancet.

[81]  J. Ferrara,et al.  Immunobiology of acute graft-versus-host disease. , 2003, Blood reviews.

[82]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[83]  E. Guinan,et al.  Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation , 2003, Transplantation.

[84]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[85]  J. Falkenburg,et al.  Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. , 2002, Experimental hematology.

[86]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[87]  C. Carlo-Stella,et al.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. , 2002, Blood.

[88]  Michael Loran Dustin,et al.  The immunological synapse , 2002, Arthritis research.

[89]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[90]  N. Mahmud,et al.  Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. , 2001, Human gene therapy.

[91]  T. A. Hewett,et al.  Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. , 2001, Experimental hematology.

[92]  F. P. Nestel,et al.  Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. , 2000, Blood.

[93]  B. Blazar,et al.  A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[94]  G. Hill,et al.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.

[95]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[96]  C. Enger,et al.  Acute bleeding after allogeneic bone marrow transplantation: association with graft versus host disease and effect on survival. , 1999, Transplantation.

[97]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[98]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[99]  O. Bagasra,et al.  Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[100]  R. Steinman,et al.  The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro , 1994, The Journal of experimental medicine.

[101]  John S. Thompson,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .

[102]  D. Snover,et al.  A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantation. , 1985, Human pathology.

[103]  M. Murad,et al.  Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. , 2016, The Lancet. Haematology.

[104]  T. Braun,et al.  A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. , 2015, The Lancet. Haematology.

[105]  A. Barrett,et al.  Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation. , 2014, Tissue engineering. Part B, Reviews.

[106]  R. Herrmann,et al.  A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[107]  A. Gratwohl,et al.  The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT , 2014, Bone Marrow Transplantation.

[108]  M. Andreeff,et al.  Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. , 2013, Cytotherapy.

[109]  A. Rashid,et al.  Prognostic value of response after upfront therapy for acute GVHD , 2012, Bone Marrow Transplantation.

[110]  Jacques Galipeau,et al.  Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[111]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[112]  Kazuya Sato,et al.  Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. , 2007, Blood.

[113]  S. François,et al.  Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. , 2006, Advances in experimental medicine and biology.

[114]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[115]  J. Ferrara,et al.  Understanding the alloresponse: new approaches to graft-versus-host disease prevention. , 2002, Seminars in hematology.

[116]  J. Ferrara,et al.  Acute graft-versus-host disease does not require alloantigen expression on host epithelium , 2002, Nature Medicine.

[117]  Brown,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. , 1994, Blood.

[118]  R. Champlin.  T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. , 1990, Cancer treatment and research.